The University of Missouri Research Reactor (MURR) will supply NorthStar Medical Radioisotopes with low specific activity molybdenum-99 (Mo-99).
This agreement allows Madison, Wis.-based NorthStar to ramp up over time to 3,000 six-day curies per week. Production operations are expected to begin in the third quarter of this year with shipments to pharmacies shortly thereafter.
NorthStar’s approach produces LSA molybdenum-99 without using uranium as the source material. LSA molybdenum-99 produced will be transferred to NorthStar’s patented TechneGen generator system, which makes this process viable. The high specific activity (HSA) technetium-99m produced will meet the U.S. Pharmacopeia requirements, according to the company.